source
- Oak Hill takes SPAC track to Nasdaq with Roche asset in towOak Hill Bio is developing the antisense therapy rugonersen, which it licensed from Roche in 2025, for Angelman syndrome.
- Eli Lilly tops new biopharma ranking on launch success, development speedFlush with GLP-1 cash and pipeline success, Eli Lilly rose from 16th to first over five years in Norstella’s inaugural Pipeline-to-Patient Productivity Index, which evaluated 25 large, global bioph…